ACADIA PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
ACAD$18.28+10.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Accumulated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||||
| Common Stock · Paid-in · Accumulated · Comprehensive · Stockholders’ | |||||||||||
| Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||||||
| Balances at December 31, 2020 | 159,637,771 | $16 | $2,612,663 | $(1,985,706) | $36 | $627,009 | |||||
| Issuance of common stock from exercise of stock options and units | 1,078,074 | — | 12,850 | — | — | 12,850 | |||||
| Issuance of common stock pursuant to employee stock purchase plan | 296,850 | — | 5,312 | — | — | 5,312 | |||||
| Net loss | — | — | — | (167,870) | — | (167,870) | |||||
| Stock-based compensation | — | — | 63,821 | — | — | 63,821 | |||||
| Other comprehensive loss | — | — | — | — | (228) | (228) | |||||
| Balances at December 31, 2021 | 161,012,695 | 16 | 2,694,646 | (2,153,576) | (192) | 540,894 | |||||
| Issuance of common stock from exercise of stock options and units | 721,652 | — | 3,705 | — | — | 3,705 | |||||
| Issuance of common stock pursuant to employee stock purchase plan | 330,525 | — | 4,494 | — | — | 4,494 | |||||
| Net loss | — | (215,975) | (215,975) | ||||||||
| Stock-based compensation | — | — | 68,078 | — | — | 68,078 | |||||
| Other comprehensive loss | — | — | (783) | (783) | |||||||
| Balances at December 31, 2022 | 162,064,872 | 16 | 2,770,923 | (2,369,551) | (975) | 400,413 | |||||
| Issuance of common stock from exercise of stock options and units | 2,236,849 | — | 20,309 | — | — | 20,309 | |||||
| Issuance of common stock pursuant to employee stock purchase plan | 348,498 | — | 4,820 | — | — | 4,820 | |||||
| Net loss | — | — | — | (61,286) | — | (61,286) | |||||
| Stock-based compensation | — | — | 66,500 | — | — | 66,500 | |||||
| Other comprehensive income | — | — | — | — | 999 | 999 | |||||
| Balances at December 31, 2023 | 164,650,219 | $16 | $2,862,552 | $(2,430,837) | $24 | $431,755 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.